Christopher Haqq, EVP, R&D & Chief Scientific Of at Atara Biotherapeutics, Inc. (ATRA), sold 27,950 shares at $38.55 ($1.1M) on 2019-02-11, disclosed to the SEC on 2019-02-11.
Seasonal sale ($1.1M) by EVP, R&D & Chief Scientific Of — this insider has traded ATRA in February in at least three consecutive prior years. Pattern-driven, low signal.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $38.55 | 13,975 | $539K | 50.0% |
| 2 | $38.55 | 13,975 | $539K | 50.0% |
| Total | $38.55 avg | 27,950 | $1.1M | 100% |
| Filing → |
| ATRA | SELL | 2018-11-15 | $26K | — | Filing → |
| ATRA | SELL | 2018-09-27 | $582K | — | Filing → |
| ATRA | SELL | 2018-09-25 | $2.0M | — | Filing → |